Charles River Laboratories has expanded manufacturing capacity in Dublin, introducing automated production equipment and a dedicated depyrogenation suite for laboratory glassware used in pharmaceutical and biotechnology quality control.
The investment establishes Dublin as an additional manufacturing location for the company's Endosafe Accessories range, which includes laboratory consumables used in bacterial endotoxin testing.
Twelve accessory glassware formats have been transferred into production at the Irish facility. The expansion also includes three validated depyrogenation ovens and custom automation intended to improve manufacturing consistency and reduce manual handling.
Charles River confirmed the development on 12 November as part of a wider programme of investment across its Microbial Solutions operations. The Dublin project increases capacity for laboratory consumables supplied to pharmaceutical, biotechnology and medical device manufacturers.
Bacterial endotoxin testing forms part of the quality control arrangements used for products and materials where the presence of endotoxins could present a patient safety risk.
Endotoxins are associated with the outer membranes of Gram-negative bacteria. Their biological activity creates particular requirements for testing and contamination control in susceptible pharmaceutical products and manufacturing processes.
The destruction of living bacteria does not necessarily remove the endotoxins associated with them. Consequently, sterilisation and depyrogenation address different aspects of contamination control and cannot be treated as interchangeable processing methods.
Laboratory testing equipment must also be suitable for the analytical procedure. Glassware used for collecting, preparing or transferring samples can introduce contamination if its condition is not appropriately controlled.
Charles River's Endosafe portfolio includes instruments, reagents and consumables used in bacterial endotoxin testing. Its accessory glassware is intended to support the preparation and handling of materials during these procedures.
The manufacturing requirements extend beyond producing an item with the correct dimensions. The finished consumable must be suitable for its intended analytical use, including the relevant requirements for cleanliness, handling and packaging.
Glassware production can involve several processing and inspection stages. Their exact sequence depends on the product format and specification, with completed items requiring appropriate treatment before release.
The new Dublin production suite incorporates custom automation to support these manufacturing activities. Charles River says the equipment improves efficiency, consistency and quality control while reducing manual handling.
Automated handling can help maintain repeatable movement and positioning of components, provided the machinery is correctly configured for their dimensions and physical characteristics.
Glass components require careful handling during transfer between operations. Incorrect contact forces or unsuitable support arrangements can damage a component or affect its condition, creating additional inspection or rejection requirements.
The company has not disclosed the individual automation systems installed in Dublin or the proportion of production operations now performed automatically. No increase in output per employee or reduction in manufacturing defects has been quantified.
Three validated depyrogenation ovens form a separate part of the expansion. The treatment process is designed to eliminate endotoxins from suitable glassware before subsequent sterile processing.
Dry-heat depyrogenation is commonly used for laboratory glassware capable of withstanding the required temperatures. The process exposes products to controlled thermal conditions intended to reduce endotoxin contamination to the specified level.
Validation requires evidence that the treatment performs consistently under the defined operating conditions. Temperature distribution, exposure time, loading arrangements and the characteristics of the products being treated can influence the result.
Reaching a specified oven temperature does not independently establish that every item in a load has received an effective treatment. The process must be assessed against its validated operating parameters, including the conditions experienced by products within the load.
Charles River has confirmed that all three Dublin ovens are validated but has not disclosed their capacities, operating temperatures or cycle times. These details would be necessary to calculate the maximum throughput of the depyrogenation suite.
After treatment, suitable handling and packaging arrangements are needed to maintain the condition of the glassware before it reaches the customer. The controls applied depend on the product specification and the requirements of its intended use.
The twelve formats now manufactured in Dublin extend Charles River's existing Endosafe production network. The company has not identified each format individually or provided a new annual output figure for the Irish operation.
Adding another production location can provide greater flexibility in responding to changes in customer demand or manufacturing requirements. The extent to which work can be distributed between sites depends on product qualification, manufacturing capacity and the arrangements established for maintaining consistent quality.
Manufacturing transfer also requires coordination between engineering, procurement and quality functions. Equipment settings, component specifications and inspection procedures must be established at the receiving facility before products can be manufactured consistently.
The successful transfer of twelve formats confirms that Dublin is already producing the selected glassware. It does not establish that every Endosafe accessory manufactured elsewhere has been transferred to Ireland.
Charles River says the project has created new employment opportunities locally, although the number of positions and the financial value of the investment have not been disclosed.
The wider Microbial Solutions investment programme includes a new instrument service depot in South Korea, providing a regional location for complex maintenance and repair activities.
The depot supports customers in South Korea, Australia, Singapore, India and China, alongside distributor-supported markets elsewhere in Asia-Pacific.
Locating service capability closer to customers can reduce some of the transport and coordination involved in returning instruments for maintenance, although turnaround time still depends on the work required, available components and equipment condition.
Charles River has also reported environmental improvements within its laboratory network, including reduced energy and water consumption. Those results relate to the wider Microbial Solutions sustainability programme and should not be attributed directly to the new Dublin manufacturing suite.
The company continues to expand manufacturing and service capacity supporting quality control workflows in regulated life-sciences production. Its Dublin facility is now manufacturing twelve Endosafe glassware formats, with the additional depyrogenation equipment providing validated treatment capacity for those consumables.
